Biotechnology

Annexon

Annexon released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.23 (forecast USD -0.2917)

Annexon released FY2025 Annual Earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.3445 (forecast USD -1.387)

Annexon released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.28 (forecast USD -0.3157)

Annexon released FY2025 9 Months Earnings on November 10 (EST), actual revenue USD 0, actual EPS USD -1.0792

Annexon released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3699 (forecast USD -0.3413)

Annexon released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3399 (forecast USD -0.367)

Annexon released FY2025 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -0.7109

Annexon's vonaprunment selected for EMA's PDC pilot program

Annexon VP Reports Disposal of Common Stock

Michael Overdorf Sells Annexon Inc. Common Stock

Annexon Inc. Reports Disposition of Common Stock

Annexon Unveils Strategic Plan for GBS and GA Treatment

Annexon Inc. Appoints Executive to Lead Ophthalmic Drug Clinical Trial

Annexon Inc. Elects New Directors and Approves New Auditor

Annexon Advances Novel Therapies for Severe Complement-Mediated Neuroinflammatory Diseases

Annexon Grants Incentive Awards to New Employees

Annexon Grants Equity Awards to Two New Non-Executive Employees

Annexon released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.367 (forecast USD -0.2959)

Annexon Inc reports Q1 loss of 37 cents per share

Annexon Inc. Announces Promising Trial Results for Tantrurubart in Treating GBS

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

ANNX

Annexon Biosciences shareholders approved director elections, executive compensation, KPMG appointment, and increased authorized shares to 500 million at the June 11, 2026 meeting. Analysts maintain a 'Hold' rating with a $7.00 target. TipRanks AI 'Spark' rates ANNX as Neutral, citing weak financials, pre-revenue status, net losses, and cash burn risks despite its focus on complement system therapies.

Tip Ranks

Annexon Stockholders Approve Directors, Compensation and Share Increase

Annexon executives outlined upcoming catalysts at the Goldman Sachs Healthcare Conference. Key focus includes Q4 Phase III data for vonaprument in geographic atrophy, targeting vision preservation via neuroprotection. Additionally, the company reported positive Phase III results for tanruprubart in Guillain-Barré syndrome, with European approval expected in early 2027 and imminent U.S. filing.

Market Beat

Goldman Sachs

GS Hldg R

Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead

Annexon (NASDAQ: ANNX) executives outlined three major pipeline catalysts at the Jefferies Conference. Key updates include a Phase III geographic atrophy readout expected in Q4, with management citing significant vision preservation in Phase II data. Additionally, the company plans to release FORWARD study data for Guillain-Barré syndrome before the U.S. filing in 2026 and provide early data on its oral complement program, ANX1502.

Apellis Pharma

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout

CDNL

On June 1, insider buying reports highlighted two transactions. Muneer A. Satter purchased 613,497 shares of Annexon (ANNX) for $3.32M at $5.41/share, marking his third buy in a year. Meanwhile, Cardinal Infrastructure Group COO Benjamin Wood bought $1.03M worth of CDNL shares at $51.30 each. Both stocks saw positive trading performance on Monday, with ANNX up 2% and CDNL up 3.4%, leaving both insiders in the green.

nasdaq

Cardinal Infrastructure

Nasdaq

Monday 6/1 Insider Buying Report: ANNX, CDNL

LABU

SBIO

IBBQ

Annexon (NASDAQ: ANNX) CEO Doug Love presented the company's late-stage pipeline at the Bank of America Healthcare Conference, focusing on geographic atrophy data expected in Q4 and regulatory filings for Guillain-Barré syndrome. The Phase 3 study for geographic atrophy involves 659 patients, aiming to demonstrate visual acuity benefits. Annexon has also filed for approval in Europe for Guillain-Barré syndrome and plans to file in the U.S. this year, emphasizing a single-infusion treatment approach.

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference

The Goldman Sachs Group upgraded Annexon (NASDAQ:ANNX) to a "hold" rating. Other analysts have varied opinions, with Chardan Capital maintaining a "buy" rating and a $16 price target, while Weiss Ratings issued a "sell" rating. Annexon shares opened at $5.44, with a market cap of $891.29 million. Recent insider sales included CFO Jennifer Lew and EVP Michael Overdorf. Institutional investors have increased their stakes, indicating growing interest. Positive sentiment surrounds Annexon as earnings estimates for future years have been lifted, reflecting improved confidence in the company's outlook.

Annexon (NASDAQ:ANNX) Upgraded by The Goldman Sachs Group to "Hold" Rating

HC Wainwright has raised its FY2030 EPS estimate for Annexon, Inc. to $0.56 from $0.43, while the consensus estimate for the current year is ($1.13) per share. The stock has received mixed ratings from analysts, with five Buy ratings, one Hold, and one Sell. Annexon shares opened at $5.69, with a market cap of $932.25 million. Recent insider sales and institutional investments have also been noted, indicating active trading around the stock. The company focuses on developing therapies for neurodegenerative diseases.

Direxion S&P Biotech Bear 3X

Arcadian Asset

HC Wainwright Has Optimistic View of Annexon FY2030 Earnings

Annexon (NASDAQ:ANNX) reported quarterly earnings of ($0.23) EPS, surpassing expectations by $0.07. The stock traded down to $5.52 with a market cap of $897.06 million. Analysts have mixed ratings, with five recommending a Buy and one a Sell. Recent insider sales totaled 32,513 shares. Institutional investors have also shown interest, acquiring new positions. Annexon focuses on complement-targeted therapies for neurodegenerative diseases, with its lead product, ANX005, in Phase 2 trials.

Annexon (NASDAQ:ANNX) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Annexon CEO Doug Love announced at the Needham Healthcare Conference that 2026 will be a "win year" for the company, highlighting key milestones in their clinical pipeline. The company anticipates filing for U.S. approval for Guillain-Barré syndrome (GBS) later this year and expects phase III results for geographic atrophy (GA) by Q4. Love emphasized their unique approach targeting C1q to block inflammation in diseases like GA and GBS, contrasting it with traditional downstream strategies. He also discussed the promising outcomes from their phase II studies and the design of the ongoing phase III ARCHER II trial.

Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing

Annexon(ANNX.US)